Tessera Defense and Homeland Security Inc. HLSQ

Company Overview

BiomX Inc. is a clinical-stage biotechnology company focused on the discovery and development of precision phage therapies designed to target pathogenic bacteria associated with chronic diseases. The company operates within the biotechnology, microbiome, and infectious disease sectors, with a primary emphasis on bacteriophage-based therapeutics intended to treat conditions where antibiotic resistance or microbiome imbalance is a significant clinical challenge. BiomX’s core pipeline has included programs targeting cystic fibrosis-associated pulmonary infections, diabetic foot osteomyelitis, inflammatory bowel disease, and other microbiome-related disorders.

The company’s primary revenue and value drivers are tied to its therapeutic development pipeline, strategic collaborations, and intellectual property surrounding phage engineering and microbiome technologies. BiomX originated from microbiome and phage research conducted at the Weizmann Institute of Science and was formed through the merger of BiomX Ltd. and the publicly traded Chardan Healthcare Acquisition Corp. The company has positioned itself as a specialized developer of customized phage cocktails and precision bacterial targeting platforms, differentiating itself from broader antibiotic-focused biotechnology companies through its bacteriophage expertise and microbiome-oriented therapeutic strategy.

Business Operations

BiomX primarily operates through its therapeutic development platform focused on engineered and naturally occurring bacteriophages. Its principal business activities include research and development, clinical trial execution, intellectual property development, and strategic partnerships related to microbiome therapeutics. Key pipeline assets have included programs such as BX004 for chronic pulmonary infections in cystic fibrosis patients and BX211 for diabetic foot osteomyelitis. The company generates limited revenue, with financial activity primarily associated with collaboration agreements, licensing arrangements, grants, and capital markets financing rather than commercialized product sales.

The company maintains operations in both the United States and Israel, combining clinical development capabilities with microbiome research infrastructure. BiomX controls proprietary phage discovery, screening, and formulation technologies intended to identify bacterial targets while preserving beneficial microbiota. Strategic collaborations have included relationships with academic institutions and healthcare research organizations supporting microbiome and infectious disease studies. Public disclosures and regulatory filings indicate that BiomX continues to prioritize clinical-stage advancement rather than diversified commercial operations.

Strategic Position & Investments

BiomX’s strategic direction centers on advancing precision phage therapies as alternatives or complements to conventional antibiotics, particularly in areas with high unmet medical need and growing antimicrobial resistance concerns. The company has invested significantly in clinical development programs targeting multidrug-resistant bacterial infections and microbiome-associated diseases. Its strategy has emphasized personalized or semi-customized phage treatments capable of selectively targeting harmful bacteria while reducing disruption to healthy microbial ecosystems.

The company has also pursued investment in proprietary phage engineering capabilities, manufacturing processes, and microbiome analytics platforms. BiomX has historically explored collaborations with pharmaceutical and academic partners to accelerate clinical validation and platform scalability. Its focus on bacteriophage therapeutics places it within an emerging biotechnology segment receiving increased scientific and regulatory attention, although commercial adoption of phage-based therapies remains in early-stage development globally. Data regarding long-term commercial scalability and future licensing expansion remains dependent on clinical outcomes and regulatory progress.

Geographic Footprint

BiomX maintains a multinational operational presence anchored by activities in the United States and Israel. The company’s corporate and clinical functions are primarily tied to the U.S. biotechnology market, while portions of its scientific research and microbiome technology development originate from Israeli research infrastructure and scientific collaborations associated with the Weizmann Institute ecosystem.

Its clinical and regulatory activities have primarily focused on the North American market, particularly U.S.-based trials and regulatory engagement with the Food and Drug Administration. BiomX’s scientific positioning and investor outreach also provide visibility within broader global biotechnology markets, including parts of Europe and international infectious disease research communities. Publicly available information does not indicate a large-scale commercial operating footprint outside research, development, and clinical trial activities.

Leadership & Governance

BiomX’s leadership team combines biotechnology, pharmaceutical development, microbiome science, and capital markets experience. The company has historically emphasized scientific innovation, precision medicine, and translational microbiome research as central components of its governance and operating philosophy. Management communications and investor materials have consistently highlighted disciplined clinical development, targeted therapeutic applications, and advancement of bacteriophage science into regulated therapeutic products.

Key executives and leadership figures have included:

• Jonathan Solomon – Chief Executive Officer
• David Almog – Co-Founder and Chairman
• Moran Ben-Yosef – Chief Financial Officer
• Assaf Oron – Chief Business Officer
• Yehuda Chowers, M.D. – Chief Medical Officer

The company’s governance structure reflects its status as a publicly traded clinical-stage biotechnology company, with oversight responsibilities managed through a board of directors and executive leadership experienced in drug development, finance, and microbiome research. Executive composition and titles may change over time based on corporate filings and governance updates.